MetaCap

Aldeyra Therapeutics (ALDX) vs Heron Therapeutics (HRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Heron Therapeutics (HRTX) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 76.2% versus a loss of 83.1%. Over five years, ALDX leads with a -89.1% price change compared with -97.3% for HRTX. Aldeyra Therapeutics is the larger company by market cap ($50.7 million vs $48.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALDX-83.06%HRTX-76.18%
+47%-24%-95%
Nov 21, 20251 yearNov 20, 2026
ALDX-89.41%HRTX-97.51%
+47%-29%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALDX versus HRTX key metrics
MetricALDXHRTX
Share price$0.84$0.2525
Market cap$50.70M$48.04M
1-day change+16.39%-4.39%
YTD return-83.78%-80.58%
1-year return-83.06%-76.18%
5-year return-89.06%-97.32%
EPS (TTM)$-0.31$-0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$154.90M
Revenue growth (YoY)—+7.36%
Net income (latest FY)$-33.85M$-20.20M
Gross margin—73.31%
Operating margin—-1.64%
Net margin—-13.04%
52-week high$5.93$1.58
52-week low$0.527$0.2479
Distance from 52-week high-85.83%-84.02%
Analyst consensusstrong_buynone
Avg. price target upside+685.71%+2672.28%
Average volume1.16M4.56M
Shares outstanding60.36M190.27M
Employees6128
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aldeyra Therapeutics

ALDX stock →

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Heron Therapeutics

HRTX stock →

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

ALDX vs HRTX FAQ

Which is bigger, Aldeyra Therapeutics or Heron Therapeutics?

Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $50.70M compared with $48.04M for Heron Therapeutics (HRTX).

Which stock has performed better over the past year, ALDX or HRTX?

HRTX returned -76.18% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.

Are Aldeyra Therapeutics and Heron Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons